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Abstract
Background: Whole-exome sequencing (WES) has been successful in identifying genes that cause familial
Parkinson’s disease (PD). However, until now this approach has not been deployed to study large cohorts of
unrelated participants. To discover rare PD susceptibility variants, we performed WES in 1148 unrelated cases
and 503 control participants. Candidate genes were subsequently validated for functions relevant to PD based
on parallel RNA-interference (RNAi) screens in human cell culture and Drosophila and C. elegans models.
Results: Assuming autosomal recessive inheritance, we identify 27 genes that have homozygous or compound
heterozygous loss-of-function variants in PD cases. Definitive replication and confirmation of these findings were
hindered by potential heterogeneity and by the rarity of the implicated alleles. We therefore looked for potential
genetic interactions with established PD mechanisms. Following RNAi-mediated knockdown, 15 of the genes
modulated mitochondrial dynamics in human neuronal cultures and four candidates enhanced α-synuclein-
induced neurodegeneration in Drosophila. Based on complementary analyses in independent human datasets,
five functionally validated genes—GPATCH2L, UHRF1BP1L, PTPRH, ARSB, and VPS13C—also showed evidence
consistent with genetic replication.
Conclusions: By integrating human genetic and functional evidence, we identify several PD susceptibility
gene candidates for further investigation. Our approach highlights a powerful experimental strategy with
broad applicability for future studies of disorders with complex genetic etiologies.
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Background
Next-generation sequencing (NGS) approaches have re-
cently accelerated the identification of variants respon-
sible for familial Parkinson’s disease (PD) [1–4]. While a
positive family history is common in PD, large, multi-
generational pedigrees, especially with available DNA
and clinical evaluations, remain exceptional, hindering
progress in unraveling the genetic underpinnings.
Importantly, several genes initially discovered to cause
PD in families, such as LRRK2, GBA, and PARK2/parkin,
were subsequently discovered with surprisingly high fre-
quency in “sporadic” PD cohorts [5, 6]. To date, large
population samples of individuals with PD have primar-
ily contributed to the discovery of common variant
susceptibility loci, based on genome-wide association
studies (GWAS) of case/control cohorts [7]. The vari-
ants identified by GWAS have modest effect sizes and
collectively fail to account for current estimates of PD
heritability [8, 9]. Considering the above, it seems likely
that additional less common alleles, with larger effect
sizes, contribute to PD risk in the population and NGS
is one promising approach to identify such alleles. Des-
pite recent successes in other neurodegenerative disease
with complex genetic etiologies, including Alzheimer’s
disease [10–12] and amyotrophic lateral sclerosis [13,
14], sequencing has yet to be deployed in large, unre-
lated PD case/control samples for rare variant discovery.
The successful discovery of rare variant risk alleles in
population-based PD samples faces a number of poten-
tial challenges. Perhaps most importantly, analyses of
rare variants in large family pedigrees is greatly facili-
tated by segregation analysis which is not possible in co-
horts of unrelated individuals, leading to an increased
number of candidate variants to consider. Assumptions
of a recessive inheritance model and the application of
stringent filters, such as consideration of only strongly
damaging, loss-of-function (LoF) variants, is one poten-
tial solution, but this is likely to miss many important
variants, including dominantly acting alleles. Further, PD
is characterized by extensive genic and allelic heterogen-
eity and extremely large cohorts may be required to
document sufficient numbers of cases to facilitate
meaningful statistical comparisons [15]. Lastly, as PD
is: (1) common (~1–3% prevalence); (2) strongly age-
dependent; and (3) often preceded by a prolonged pre-
symptomatic or minimally symptomatic phase, we may
expect to find truly pathogenic rare variants, including
those with large effect sizes, in “control” cohorts of
adults (due to unrecognized or early disease stages with
minimal symptoms). Therefore, given the occurrence of
rare variants, including potentially damaging variants, in
most genomes of presumably healthy individuals [16], it
may be difficult to identify genes/variants that truly
cause disease. Importantly, recent advances in cellular
and animal models, along with improved understand-
ing of PD pathogenesis, enable an integrated ap-
proach, in which variant discovery is coupled with a
functional screening pipeline for prioritization of
those genes worthy of more intensive study.
In this collaborative study of the International Parkinson’s
Disease Genomics Consortium (IPDGC), we report the
results of whole-exome sequencing (WES) in 1148 PD
cases, the largest such cohort examined to date. Con-
sistent with the younger age of PD onset in this cohort,
which is often associated with a recessive inheritance
[17–19], and to prioritize candidate genes/variants for
initial investigation, our analysis focuses on genes with
homozygous or compound heterozygous LoF variants.
We further couple the human genetic studies with
functional screening in mammalian cell culture and in-
vertebrate animal models, successfully identifying those
candidate genes showing interactions with established
PD mechanisms, including mitochondrial dynamics and
α-synuclein-mediated neurodegeneration. Although no
sufficiently powered exome dataset was available for
definitive replication, human genetic validation was
undertaken in several independent datasets. Our inte-
grated approach identifies five strong candidate PD sus-
ceptibility genes worthy of further investigation, and
exemplifies a powerful strategy with potential broad ap-
plicability to the follow-up of future rare variant studies
in PD and other neurologic disorders with complex
genetic etiologies.
Results
Discovery of recessive LoF variants from PD exomes
A total of 920,896 variants (93.2% single nucleotide var-
iants and 6.8% insertions and deletions) were called in
a WES dataset of 1651 participants, including 1148
young-onset PD cases (average age of onset, 40.6 years;
range, 5–56 years) and 503 control participants with
European ancestry. As our cohort has an average age at
onset of less than 45 years, we focused our search on
homozygous and putative compound heterozygous var-
iants, consistent with a recessive inheritance model. Al-
though most PD cases were prescreened for mutations
in established PD genes, we identified two participants
with homozygous exonic variants in parkin and PINK1
(Additional file 1: Table S1). In order to identify novel
PD gene candidates, we focused on variants that are
rare in control populations. Considering the worldwide
prevalence for PD (0.041% in individuals aged 40–49
years) [20], we used a minor allele frequency (MAF)
threshold of 1% and only considered LoF variants causing
a premature stop codon or splicing site mutations (see
“Methods”). When co-occurring with a heterozygous LoF
variant, we also considered rare, heterozygous amino-
acid changing missense alleles that were predicted to be
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deleterious (CADD > 20), consistent with a compound
heterozygous recessive genotype.
Figure 1 displays each variant filtering step along with
the corresponding numbers of implicated variants. Fol-
lowing Sanger sequencing confirmation, we identified a
total of 27 candidate genes—18 genes encompassing
homozygous variants and nine genes harboring putative
compound heterozygous variants—all predicted to cause
a loss of gene function (Table 1). Approximately 17% of
the variants are absent in public allele frequency data-
bases (1000 Genomes Project (1000G), Exome Sequen-
cing Project v. 6500 (ESP6500), or Exome Aggregation
Consortium (ExAC)) and therefore implicated to be
novel. Except in the case of ARSB, the other 26 genes
harbor LoF variants in only a single case, consistent with
the hypothesis that novel recessive PD alleles may con-
sist of many rare, “private” mutations. Four PD cases in
our cohort were identified with a LoF variant in the
ARSB gene, in which mutations have previously been
linked with the recessive lysosomal storage disorder,
MPS VI (also called Maroteaux-Lamy syndrome). All
four individual cases, along with one control participant,
were homozygous for a variant (rs138279020) predicted
to disrupt splicing. Although this variant is neither re-
ported in ExAC nor was frequency information avail-
able from dbSNP, the MAF was 0.065 in our cohort
(MAFCASES = 0.073, MAFCONTROLS = 0.052, p = 0.054).
Although relatively frequent in our control dataset
(MAF > 1%), we have retained it among our results,
based on three considerations. First, information was
not present in dbSNP, ExAC, or ESP6500, which was
the basis for applying this frequency filter in all other
cases. Second, at least one of the homozygous individ-
uals had clinical manifestations consistent with MPS
VI, supporting potential pathogenicity of this allele (see
“Discussion”). Lastly, as detailed below, our functional
Fig. 1 Flowchart explaining multiple filtering steps to select LoF variants with assumed recessive inheritance pattern. Functional annotation was
performed with transcripts of RefSeq and UCSC databases. MAF annotations were based on 1000 Genomes project, Exome variant Server, and the
ExAC database. Seventeen genes harbored homozygous variants causing stopgain or loss and one gene contained a homozygous splicing
variant. For the putative compound heterozygous genes, six genes were selected based on the presence of two LoF variants, and three genes
were based on the presence of one LoF variant and one missense variant (predicted to belong to the 1% most harmful variants of the genome)
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studies identify links between manipulation of ARSB
and cellular/organismal phenotypes consistent with a
potential role in PD.
Of note, while the analyses of the IPDGC WES dataset
and subsequent work described here were in progress,
an independent family-based sequencing study identified
VPS13C as a cause of autosomal recessive parkinsonism
[21]. Although the single IPDGC subject with compound
heterozygous VPS13C LoF alleles was published as a
replicate case in that work, we retained it among the 27
candidates described here, since it was independently
carried forward for all analyses detailed below.
Tolerability of gene LoF in humans and animal models
The “tolerability” of recessive LoF genotypes has import-
ant implications for understanding the genetic basis of
adult-onset, age-influenced disorders such as PD. As
most of the identified homozygous and putative com-
pound heterozygous LoF genotypes are based on a single
individual, we also examined for their occurrence in a
large, recently published study [16] of predicted
complete gene knock-outs in the Icelandic population,
including 104,220 participants with imputed genotypes,
based on whole genome sequencing from a subset of
2363 individuals. The Icelandic population is enriched
for rare disease-causing mutations with a recessive in-
heritance pattern, given a strong founder effect and
non-random mating patterns. Twelve of the variants
that we identified are also present in the Icelandic study
(Additional file 1: Table S2); however, the observed
homozygote frequencies are not sufficiently high to
confidently exclude them as possible PD genes and im-
portantly, detailed phenotypic data are not publicly avail-
able for these participants. For example, 29 Icelandic
participants are reported homozygous for the identical
PTCHD3 stopgain variant (c.C1426T, p.R476X) as the sin-
gle PD case in our WES study. However, this is only
0.028% of the total sample set and below the reported
prevalence of young-onset PD (0.041%).
We additionally examined for the presence of other
LoF variants with a recessive inheritance pattern in our
implicated candidate genes (Additional file 1: Table S2).
For a subset of genes, we indeed identified several vari-
ants with particularly high homozygote frequencies in-
cluding OR7G3 (9.16%), SSPO (9.38%), and PTCHD3
(16.55%). This is consistent with prior reports describing
a homozygous deletion covering PTCHD3 in apparently
healthy individuals, consistent with a non-essential role
[22]. Assuming that the variants in OR7G3, SSPO, and
PTCHD3 confer similar LoF to the alleles identified in
our PD WES data, their high variant frequency makes
these genes unlikely to be highly penetrant PD-risk loci.
Human genes harboring homozygous LoF variants—espe-
cially those observed recurrently in large population-based
datasets—potentially identify genes that are dispensable
for fetal and subsequent child development. Given the
limited human phenotypic information available, we
further investigated the potential tolerability for the im-
plicated genes using a cross-species approach, perform-
ing systematic LoF analysis in the nematode, C. elegans.
Out of the 27 candidate genes identified in our WES
analysis, ten were well conserved in the C. elegans gen-
ome and nine had readily available RNA-interference
(RNAi) reagents for LoF screening (see “Methods”).
Each gene was targeted for knockdown using RNAi and
we assessed for developmental lethality and survival.
The results of these studies, along with other LoF data
from public databases, are available in Additional file 1:
Table S3. Knockdown of homologs of DIS3 (dis-3),
KALRN (unc-73), and PTCHD3 (ptr-10) resulted in
developmental arrest and/or reduced survival in C. ele-
gans. Notably, homologs of KALRN and DIS3 are also
associated with reduced viability following genetic dis-
ruption in both Drosophila [23, 24] and mice [25, 26].
Thus, these results are potentially consistent with con-
served, early, and/or essential developmental roles for
these genes and the absence of individuals harboring
homozygous LoF variants in the Icelandic cohort [16].
Since the human genome contains multiple gene para-
logs for KALRN and PTCHD3, genetic redundancy
might account for how LoF might be tolerated in
humans but not in simple animal models. Alternatively,
it is possible that the allelic variants implicated in our
PD WES cohort and Icelandic study might not cause a
complete LoF (i.e. genetic null) despite the algorithmic
predictions, instead causing only a partial LoF. Never-
theless, these cross-species comparisons suggest essen-
tial and early developmental roles for homologs of
PTCHD3, DIS3, and KALRN, and informing our consid-
eration of potential contribution to adult-onset disor-
ders, such as PD.
Variant aggregation analyses
For the 27 genes implicated based on our primary ana-
lyses of homozygous or compound heterozygous LoF
variants, we additionally considered evidence for the
presence of other allelic variants conferring risk for PD
in our cohort. We therefore performed burden analyses
leveraging our IPDGC WES data, testing two nested
classes of variants: (1) a subset predicted to be deleterious
(CADD > 20); and (2) all amino-acid changing missense
alleles. Rare variants (MAF < 0.018) were considered ei-
ther selectively or in joint models with common variants
(MAF > 0.018). As detailed in Additional file 1: Table S4,
the rare variant aggregation association analyses provided
further evidence in support of four candidate genes: GH2,
PTPRH, UHRF1BP1L, and ZNF453. Interestingly, the bur-
den association at the PTPRH gene is further enhanced
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when common and rare variants are simultaneously
modeled.
Our analyses of LoF variants in PD exomes identify a
number of promising candidate genes. However, even
though a positive family history was observed for almost
40% of the cases, segregation analysis of the variants in
families is not feasible, as DNA samples are not available
from additional family members. Further, since most of
the genes implicated contribute to single or few cases,
we are unable to perform meaningful statistical compari-
sons, based on the limited numbers of LoF variants
identified by WES in cases versus controls. As an alter-
native strategy, we therefore deployed a combination of
cell-based and model organism functional screens to
define potential links between the 27 candidate genes
(Table 1) and well-established mechanisms of PD sus-
ceptibility and pathogenesis, including (1) mitochondrial
health and (2) α-synuclein-mediated toxicity.
Functional prioritization: mitochondrial health
Although the mechanism of neurodegeneration in PD
remains incompletely defined and may be heteroge-
neous, mitochondrial dysfunction has been proposed to
play an important role, particularly in young onset PD
[27–29]. Notably, parkin (PARK2), DJ-1, and PINK1,
associated with autosomal recessive, juvenile-onset
Parkinsonism, have roles in mitochondrial dynamics and
quality control [30]. Specifically, Parkin is an E3 ubiqui-
tin ligase and recruited selectively to dysfunctional mito-
chondria with a low membrane potential [31]. Further,
the neurotoxicity of α-synuclein, the primary constituent
of Lewy body inclusions in PD, has also been linked to
mitochondrial injury [32]. We therefore hypothesized
that LoF in candidate genes identified from our analyses
of WES, might similarly impact mitochondria, consistent
with roles in PD susceptibility.
Therefore we quantified mitochondrial morphology
after gene knockdown in BE(2)-M17 neuroblastoma cells
by examining three parameters commonly used for
quantification of mitochondrial morphology: mitochon-
drial number, axial length ratio, and roundness [33].
Cells transduced with the short hairpin RNA (shRNA)
encoding a scrambled sequence were used for
normalization and positive controls for mitochondrial
morphology were included in each experiment. For ex-
ample, knockdown of the mitochondrial fission gene
dynamin 1-like (DNM1L), a positive control, results in
elongated mitochondria and therefore decreases mito-
chondrial axial length ratio and roundness (Fig. 2a, b)
[34]. Knockdown of 13 genes show a significant effect
on at least one of the three parameters (Additional file 1:
Table S5 and Table S6 and Additional file 2: Figure S1).
GPATCH2L shows the largest increase in mitochondrial
roundness, while UHRF1BP1L displays the largest de-
crease (Fig. 2c, d).
We also took advantage of a well-established Parkin
translocation assay [31, 35–38] based on BE(2)-M17 hu-
man neuroblastoma cells stably expressing Parkin-GFP.
As expected, upon exposure to the mitochondrial toxin
and electron transport chain uncoupling reagent, CCCP,
we observed robust translocation of Parkin-GFP from
the cytoplasm (Fig. 3a, untreated) to the mitochondria
(Fig. 3a, CCCP-SCR transduced) and this was PINK1-
dependent (Fig. 3a, CCCP-PINK1 shRNA), which provides
an internal, positive control in our assay. CCCP-induced
Parkin accumulation was assessed by high-content mi-
croscopy and automated image analysis following sys-
tematic shRNA-knockdown of our 27 candidate genes
(Fig. 3b). Based on stringent criteria (see “Methods”),
six genes significantly modified Parkin translocation
(Fig. 3c and d; Additional file 2: Figure S2; Additional
file 1: Table S5 and Table S6), including four genes
(GPATCH2L, PTCHD3, SVOPL, and ZNF543) with con-
sistent activities in both the mitochondrial morphology
and Parkin translocation assays.
Functional prioritization: α-synuclein-mediated toxicity
A wealth of evidence also supports a central role for α-
synuclein-mediated toxicity in PD pathogenesis. α-
synuclein aggregates, termed Lewy bodies, are the defining
disease pathology and α-synuclein gene (SNCA) muta-
tions, locus multiplication, and promoter polymorphisms
are associated with PD susceptibility [5]. Further, expres-
sion of α-synuclein in numerous animal models including
in the fruit fly [39–41], Drosophila melanogaster, recapitu-
lates features of PD-related neurodegenerative pathology.
Transgenic expression of α-synuclein in the fly retina
leads to neurotoxic changes [39] and is amenable for de-
tection of genetic modifiers [42, 43]. Genetic manipulation
of established PD susceptibility genes, including PARK2
[44, 45] and VPS35 [46], modulate α-synuclein toxicity in
transgenic flies, similar to findings in mammalian models
[44, 47]. We therefore hypothesized that LoF in homologs
of novel PD genes may similarly enhance α-synuclein-
induced retinal degeneration.
Out of the 27 candidate genes implicated by our
WES analyses, 13 were well-conserved in Drosophila
(Additional file 1: Table S7). Available RNAi stocks
targeting each of the 18 fly homologs (some genes had
multiple conserved paralogs) were crossed to flies in
which the human α-synuclein transgene was directed
to adult photoreceptors using the Rhodopsin1-GAL4
(Rh1) driver (Rh1 > α-synuclein) [48]. For rapid screen-
ing, retinal neurodegeneration was monitored using
the optical neutralization technique which allows as-
sessment of retinal tissue integrity in intact, unfixed
heads. In Rh1 > α-synuclein animals, the retina appears
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morphologically normal at 1 day (Fig. 4), but demonstrates
age-dependent degeneration leading to progressive vacu-
olar changes, rhabdomere loss, and culminating with ex-
tensive tissue destruction by 30 days. At the 15-day time
point selected for screening, only mild, if any, retinal
pathology is detectable on most histologic sections, con-
sistent with a weakly penetrant degenerative phenotype
following optical neutralization (mean penetrance ~25%)
(Fig. 4). However, co-expression of RNAi targeting fly
homologs of four candidate genes (ARSB, TMEM134,
A
C
B
D
Fig. 2 High-content assay for mitochondrial morphology. Effect of DNM1L shRNA (a, b) and UHRF1BP1L shRNA (c, d). BE(2)M17 cells stained with
Hoechst (blue; nuclei), MitoTracker CMXros, and MitoTracker Deepred (yellow; mitochondria). a Cells infected with shRNA encoding a scrambled
sequence (SCR, left panel) and decrease in mitochondrial axial length ratio and roundness for DNM1L (positive control, right panel). b The graph
displays normalized mitochondrial roundness. c Cells infected with shRNA encoding a SCR sequence (left panel) and decrease in number of
mitochondria per cell, mitochondrial axial length ratio, and roundness for UHRF1BP1L (right panel). d The graph displays normalized mitochondrial
roundness. Data are median values ±median absolute deviation (MAD) of N = 6 measurements. *p < 0.05 and **p < 0.01, Mann–Whitney U test
(see “Methods”). All values were normalized to the negative control (infected with SCR shRNA) and all shRNA clones that meet the cutoff criteria
are shown (b, d)
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Fig. 3 High content assay for Parkin translocation. Effect of PINK1 shRNA (a, b) and GPATCH2L shRNA (c, d). a, c Cells are labeled for nuclei (blue;
Hoechst), Parkin-GFP (green), mitochondria (red, Mitotracker Deepred). Untreated cells infected with shRNA encoding a scrambled sequence show
absence of puncta (left panel). Cells infected with a scrambled sequence but treated with CCCP show a significant increase in puncta formation
(middle panel). Infection of cells with shRNA targeting PINK1 or GPATCH2L prevents the accumulation of Parkin on mitochondrial (right panel). b, d
The graph displays the normalized ratio of cells positive for translocation and cells negative for parkin translocation. All values were normalized to
the negative control (CCCP treated infected with shRNA encoding a scrambled sequence). Data are median values ± median absolute deviation
(MAD) of N = 6 measurements. *p < 0.05, **p < 0.01, and ***p < 0.001, Mann–Whitney U test (see “Methods”). All shRNA clones that meet the cutoff
criteria (see “Methods”) are shown
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PTPRH, and VPS13C) was observed to robustly enhance
α-synuclein-mediated neurodegeneration in the retina
(mean penetrance ~ 75%; Additional file 1: Table S8).
All candidate enhancers of α-synuclein identified using
the screening assay were further confirmed based on ret-
inal histology, demonstrating accelerated pathologic
changes with a significantly increased overall extent and
severity of degeneration compared to Rh1 > α-synuclein
controls without RNAi transgenes present (Fig. 5). Im-
portantly, when each of these genes were targeted under
similar experimental conditions (Rh1 > RNAi), but inde-
pendent of α-synuclein expression, we did not observe
any significant retinal pathology in 15-day-old animals
(Fig. 5). Therefore, within the Drosophila α-synuclein
transgenic model system, the implicated LoF enhancers
appear consistent with synergistic (non-additive) effects
on α-synuclein-mediated retinal degeneration. Since in-
creased α-synuclein expression levels are one important
mechanism of PD susceptibility [5], western blot ana-
lyses were performed to determine whether any of the
identified genetic enhancers alter α-synuclein protein levels.
However, following RNAi-mediated knockdown, none led
to significant changes (Additional file 2: Figure S3).
Thus, we hypothesize potential interactions with more
downstream mechanisms of α-synuclein neurotoxicity.
For 3 out of 4 candidate enhancers (ARSB, VPS13C,
PTPRH), available siRNAs permitted additional testing
of gene homologs as candidate modifiers in an estab-
lished C. elegans model of α-synuclein toxicity [49].
However, no significant differences were detected in the
α-synuclein-induced locomotor phenotype observed in
one-week-old worms following knockdown of these genes
(Additional file 2: Figure S4). We speculate that these
contradictory results might stem from differences in assay
sensitivity and/or tissue-specific toxic mechanisms as the
fly and worm models are based on α-synuclein expression
in the retina versus muscle, respectively.
Of the four genes discovered to interact with α-
synuclein toxicity in Drosophila, we were able to obtain
additional genetic reagents, including classical LoF al-
leles, for the two homologs of PTPRH: Ptp10D and
Ptp4E. In our screen, two independent RNAi lines tar-
geting Ptp10D robustly enhanced α-synuclein toxicity,
but only one of the two available lines for Ptp4E met our
threshold criteria (Additional file 1: Table S8). Interest-
ingly, prior studies in Drosophila suggest that Ptp10D
and Ptp4E are the result of a gene duplication event and
these genes show evidence of partial functional redun-
dancy, including for nervous system phenotypes [50].
Consistent with this, we found that transheterozygosity for
Fig. 4 α-synuclein-induced retinal degeneration and screening assays in Drosophila transgenic animals. Tangential sections through the fly retina
stained with hematoxylin and eosin reveal the ordered ommatidial array in control animals (a Rh1-GAL4 / +). Each ommatidia consists of a cluster
of eight photoreceptive neurons (seven visible at the level examined). The photoreceptors each contain a single rhabdomere, the specialized
organelle subserving phototransduction, giving the ommatidia cluster its characteristic appearance (arrowhead). Expression of α-synuclein in adult
photoreceptors (b, c Rh1-GAL4 / +; UAS-α-synuclein / +) causes age-dependent, progressive retinal degeneration. Compared to one-day-old Rh1
> α-synuclein flies (b), histologic sections in 30-day-old animals (c) demonstrate rhabdomere/cell loss and substantial vacuolar changes (asterisk).
The pseudopupil preparation allows visualization of rhabdomeres (arrowhead) in intact, unfixed intact fly heads, permitting medium-throughput
screening for progression of α-synuclein-induced retinal pathology. Compared to controls (d Rh1-GAL4 / +), in 30-day-old α-synuclein transgenic
animals (e Rh1-GAL4 / +; UAS-α-synuclein / +) rhabodomeres frequently appear indistinct (arrowhead) and vacuolar changes disrupt light refraction
(asterisk). Representative control histology (a) and pseudopupil images (d) are shown for 15-day-old animals, the timepoint used for screening, in
order to facilitate comparison with Fig. 5. Scale bar: 20 μm
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Fig. 5 PD gene candidates harboring LoF variants enhance α-synuclein toxicity in Drosophila. Conserved fly orthologs of human genes discovered
from WES analysis were targeted with RNAi (IR) and screened for enhancement of α-synuclein pathology using the pseudopupil assay (a top row).
For each line evaluated, the severity of retinal degeneration was scored based on penetrance of the α-synuclein pseudopupil phenotype and
enhancers required consistent results for at least two independent RNAi lines (see Additional file 1: Table S8). Representative results from the
primary screen are shown for controls (Rh1-GAL4 / +; UAS-α-synuclein / +) and one IR line each for the implicated enhancers [Human Gene-Fly
Ortholog (experimental genotype shown)]: ARSB-CG32191 (Rh1-GAL4 / +; UAS-α-synuclein / UAS-CG32191.IR.v14294), TMEM134-CG12025 (Rh1-GAL4 /
UAS-CG12025.IR.v104336; UAS-α-synuclein / +), PTPRH-Ptp10D (Rh1-GAL4 / UAS-Ptp10D.IR.v1102; UAS-α-synuclein / +), and VPS13-Vps13 (Rh1-GAL4 /
UAS-Vps13.IR.HMS02460; UAS-α-synuclein / +). At the 15-day-old time point, Rh1 > α-synuclein causes a weakly-penetrant pseuodopupil phenotype
and mild histopathologic changes which are amenable to modifier screening (compare with Fig. 4, panels c and e). Enhancers identified in the primary
screen were confirmed based on retinal histology (a middle row) and demonstrated increased tissue destruction and disorganization. Activation of
RNAi was not associated with any significant retinal degeneration in the absence of α-synuclein co-expression (a bottom row, Rh1-GAL4 / IR transgene).
Scale bars: 20 μm. b Enhancement of α-synuclein-induced retinal degeneration was quantified based on the extent of vacuolar changes (area occupied
by vacuoles / total retinal area). For quantification, three animals were examined per genotype. For PTPRH, additional confirmation was obtained by
evaluating flies doubly heterozygous for strong alleles of the paralogs Ptp10D and Ptp4e (see also Additional file 2: Figure S5). Statistical comparisons
were made using unpaired t-tests. Error bars are based on Standard Error of the Mean. *p < 0.05; **p < 0.01
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strong (null) alleles of both genes enhanced α-synuclein-
induced retinal degeneration (Ptp4E1, Ptp10D1 / +; Rh1-
Gal4 / +; UAS-α-synuclein / +); whereas heterozygosity for
either allele in isolation showed no significant enhancement
(Fig. 5b and Additional file 2: Figure S5).
Genetic replication of candidate PD genes from WES
We next evaluated our 27 gene candidates in additional
available genetic datasets including: (1) an independent
exome sequencing dataset from the Parkinson Progres-
sion Markers Initiative (PPMI) project [51]; (2) a whole-
genome sequencing dataset including PD index cases of
a Dutch genetic isolate belonging to the Genetic
Research in Isolated Population (GRIP) program [52];
(3) an independent NeuroX exome array dataset [7, 53];
and (4) a large PD GWAS dataset [53]. Within the PPMI
exome dataset, including 462 PD cases and 183 controls,
evidence supporting replication was discovered for two
genes, in which we identified the identical variants from
the IPDGC discovery exome dataset (Additional file 1:
Table S9). A PD case from PPMI carries the same
homozygous stopgain variant (p.R362X) in GPATCH2L
as observed for an IPDGC case. Although the age of
onset differs 20 years between these two PD cases (47
and 68 years for the IPDGC and PPMI patients, re-
spectively), they share similar asymmetric clinical
symptoms at onset, which are characterized by resting
tremor, bradykinesia, and rigidity. Furthermore, both
PD cases have a father diagnosed with PD, implying the
variant to be highly penetrant. We excluded the possi-
bility that these two PD cases might be related by com-
puting pairwise genetic relationships [54] from
common SNPs (MAF ≥ 0.01). No evidence of related-
ness was observed (Ajk = −0.0018). Based on ExAC, only
one (0.003%) out of 32,647 European individuals has
this same homozygous variant. The observation of two
PD cases (0.12%) of our 1610 studied PD patients (1148
IPDGC WES plus 462 PPMI WES) with this GPATCH2L
mutation is consistent with a 40-fold enrichment in our
PD cohort. The second gene harboring an identical LoF
variant is FAM83A. The p.G86X variant in FAM83A,
detected within an IPDGC participant with sporadic
PD diagnosed at the age of 28 years, was also observed
in a single sporadic PD case from PPMI with an age of
onset of 62 years. These FAM83A carriers presented
with similar symptoms, including bradykinesa, rigidity,
and resting tremor. In both datasets, the p.G86X allele is
predicted to be in trans with another variant: p.R347X or
p.V137G in PPMI and IPDGC, respectively.
The second genetic independent dataset that was in-
vestigated included a whole-genome sequencing study
(39 PD index cases and 19 controls) of a genetic GRIP
isolate from the Netherlands, focusing on variants within
our candidate genes that were present in at least two PD
index cases and absent in controls. We identified a het-
erozygous missense variant (NM_001127444:c.1176G >
T:p.L392F) in CD36 for three PD index cases. Although
not consistent with a recessive inheritance model, this
variant has not been observed in the 60,706 unrelated
individuals of the ExAC database, suggesting potential
enrichment in PD cases. These heterozygote variant
carriers have a substantial higher age of onset (range,
61–79 years) in comparison to the PD patient (age of
onset, 38 years) with the putative compound heterozy-
gous variant within the discovery WES dataset. This
observation supports an additive model of pathogen-
icity, implying more severe disease onset when two
alleles are affected. Further, CD36 (p.L392F) is pre-
dicted to represent the top 1% most harmful variants
within the genome (CADD score = 23.3). In the IPDGC
discovery dataset, the discovered compound heterozy-
gous variants, p.Q74X and p.P412S (Table 1), are also
predicted to be strongly deleterious (CADD scores of
26.5 and 25.9, respectively).
We next interrogated the independent IPDGC NeuroX
dataset, including genotypes from 6801 individuals with
PD and 5970 neurologically healthy controls. NeuroX is
a genotyping array that includes pre-selected exonic
variants and is therefore not suitable to search for the
identical recessive LoF variants implicated by our WES
analyses. Instead, we examined the burden of multiple
variant classes within the 27 candidate genes, following
the same variant categories as for the original IPDGC
WES dataset (Additional file 1: Table S10). When only
considering variants predicted to be deleterious (CADD >
20), an association is detected for UHRF1BP1L with PD
risk (p = 0.005). This gene also shows an association with
PD in the IPDGC WES dataset when performing a similar
burden analysis considering missense variants (see above,
p = 0.016). Using the NeuroX dataset, we additionally
confirmed the enrichment of rare PTPRH variants in
participants with PD (WES: p = 0.034, NeuroX: p =
0.045). Furthermore, VPS13C and ARSB show signifi-
cant associations to PD when considering the joint ef-
fect of all variants, both common and rare (Additional
file 1: Table S10).
Leveraging available IPDGC GWAS data (13,708 cases/
95,282 controls), we next assessed for potential common
variant association signals (p < 1 × 10−4) using a 1-Mb gen-
omic window centered on each of the 27 candidate genes.
Three loci (VPS13C, PCDHA9, and TCHHL1) showed
evidence consistent with an association peak (Additional
file 2: Figure S6). A genome-wide significant association at
the VPS13C locus, was in fact recently reported [7]; the
best SNP (rs2414739, p = 3.59 × 10−12) maps ~150 kb
distal to VPS13C. Based on local patterns of linkage
disequilibrium defined by Hapmap (Additional file 2:
Figure S6), it is unlikely that rs2414739 is a proxy for
Jansen et al. Genome Biology  (2017) 18:22 Page 12 of 26
p.E3147X or similar LoF variants in VPS13C; however, it
might be possible that the SNP influences VPS13C expres-
sion by affecting the long non-coding RNA lnc-VPS13C-1
[55] in which the SNP is located. The other two candidate
association peaks, adjacent to PCDHA9 and TCHHL1, are
considerably weaker signals (rs349129 = 1.40 × 10−5 and
rs7529535 = 7.66 × 10−5, respectively) and given the dis-
tances (~500 kb) many other candidate genes are poten-
tially implicated.
In sum, we identify additional genetic evidence con-
sistent with replication for seven genes (GPATCH2L,
FAM83A, CD36, UHRF1BP1L, PTPRH, ARSB, and
VPS13C) that were implicated by our WES analysis, of
which five (GPATCH2L, UHRF1BP1L, PTPRH, ARSB,
and VPS13C) are further validated based on functional
evidence from PD-relevant experimental models.
Transcriptomics-based functional exploration
Lastly, we examined each candidate gene from our
WES analysis for co-expression with established PD
susceptibility gene in expression networks derived
from human substantia nigra, leveraging available data
from the United Kingdom Brain Expression Consor-
tium (UKBEC) and the Genotype-Tissue Expression
project [56]. Of the 27 candidate genes, seven were
not sufficiently expressed in substantia nigra on the
basis of UKBEC. Except for DIS3, these genes were
also expressed poorly in publicly available data of the
Genotype-Tissue Expression (GTEx) project [56].
Consequently, expression values for these genes were
not used for construction of the UKBEC gene co-
expression network (GCN). The remaining 20 genes
were assessed for co-expression with known Mendelian
PD genes (ATP13A2, FBXO7, LRRK2, PARK2, PARK7,
PINK1, RAB39B, SNCA, and VPS35) using the UKBEC
GCN (Additional file 1: Table S11 and Additional file 2:
Figure S7). This approach highlighted three genes
(UHRF1BP1L, GPATCH2L, and PTPRH) and the impli-
cated networks were further interrogated based on gene
set enrichment analysis using gene ontology (GO) terms
to denote potential functions. UHRF1BP1L was co-
expressed with SNCA, PINK1, GBA, and ATP13A2 in a
network significantly enriched for genes with roles in syn-
aptic transmission (p = 2.27 × 10−11) as well as astrocytic
(p = 8.18 × 10−8) and dopaminergic neuronal markers (p =
3.98 × 10−46). GPATCH2L was co-expressed with PARK7
in a network enriched for other neuronal genes (p =
3.41 × 10−12) with cellular roles in metabolism of macro-
molecules (p = 3.82 × 10−15). Lastly, PTPRH was assigned
to a co-expression module including FBX07 and enriched
for oligodendrocyte markers (p = 8.69 × 10−22). Importantly,
the implicated modules were preserved (Z.summary > =10)
in the independent GTEx dataset.
Discussion
We report the results from WES analysis in the largest
PD cohort studied to date. Assuming a recessive inherit-
ance model, we identified 27 candidate genes harboring
rare homozygous or compound heterozygous LoF vari-
ants. With the exception of ARSB, we did not identify
recurrent recessive alleles in more than a single PD case.
This result—potentially consistent with a highly hetero-
geneous genetic etiology for PD—creates significant bar-
riers for statistical confirmation and genetic replication
of novel PD susceptibility loci. Additional genetic sam-
ples were not available for segregation analysis and given
the rarity and heterogeneity of the implicated alleles, de-
finitive human genetic replication would likely require
very large sample sizes, including many thousands of PD
cases with either WES or gene resequencing. We there-
fore coupled our WES analyses with functional studies
in both mammalian cells and experimental animal
models, including Drosophila and C. elegans, in order to
prioritize genes for future study. Our results highlight 15
out of the 27 gene candidates that interact with mito-
chondrial dynamics and five loci that enhance α-
synuclein-mediated neurodegeneration. As discussed
below, while these results highlight a promising subset
of genes with potential links to PD-relevant mecha-
nisms, we cannot exclude contributions from other im-
plicated genes/variants. All of these data, including
promising variants from the human genetic analyses
and results of functional studies, will be a valuable
resource for future investigations of PD genomics.
Analyses of several other WES and complementary
large-scale, genetic datasets provide additional evidence
supporting replication for 7 out of 27 genes. Evidence
from human genetics and functional studies converge
to most strongly implicate five gene candidates dis-
cussed below; however, further investigation will be re-
quired to definitively link each of these loci to PD
susceptibility and elucidate the relevant mechanisms.
Nearly all of these genes are robustly expressed in brain
[56], including the substantia nigra, thereby consistent
with their implication in PD. A subset (GPATCH2L,
UHRF1BP1L, and PTPRH) are co-expressed with estab-
lished Mendelian PD genes in the substantia nigra
based on analyses of UKBEC and GTEx expression
data. In sum, our results define several promising new
susceptibility loci candidates for further investigation
and illustrate a powerful, integrative discovery strategy
for future, large-scale PD genomic studies.
Mitochondrial mechanisms have been strongly impli-
cated in PD risk and pathogenesis [28, 30]. Following
shRNA-mediated knockdown, 15 candidate recessive
loci identified in our WES dataset showed effects on
mitochondrial morphology and Parkin translocation to
mitochondria in cell culture. We focus our initial
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discussion on three genes, GPATCH2L, UHRF1BP1L,
and VPS13C, for which we discovered additional genetic
evidence consistent with replication in independent
cohorts. In the IPDGC cohort, a single PD case was
identified with a homozygous stopgain variant (p.R362X)
in GPATCH2L and a second individual with the identi-
cal, rare genotype was discovered in PPMI. This variant
is reported with a low frequency of 0.003% in ExAC.
Although minimal clinical or demographic information
is available within ExAC, this finding is compatible with
population prevalence estimates for PD [20]. Neverthe-
less, genotyping of p.R362X in additional large PD case
and control cohorts will be required to definitively estab-
lish an association with PD susceptibility. GPATCH2L
knockdown both increased mitochondrial roundness
and impaired Parkin translocation. The encoded protein,
GPATCH2L, which has not previously been studied,
contains a glycine-rich RNA-binding motif, the “G-
patch” domain [57]. GPATCH2, a paralog of GPATCH2L,
is upregulated in cancer cells, localizes to the nucleus
where it interacts with RNA-processing machinery, and
manipulation in culture alters cell proliferation [58, 59].
Notably, GPATCH2L is non-conserved in either the C. ele-
gans or Drosophila genomes, precluding study of this can-
didate in these models. While our results using cellular
assays implicate GPATCH2L in mitochondrial quality con-
trol mechanisms, further follow-up studies in mammalian
model systems will be needed to confirm a role in PD
pathogenesis.
Another promising gene, UHRF1BP1L, harbored a
homozygous stopgain variant (p.K1376X) in a single
IPDGC case. This is a novel variant, based on its ab-
sence from the ExAC cohort. Additional support for
UHRF1BP1L as a bona fide PD locus comes from com-
plementary analyses in both the IPDGC WES and Neu-
roX datasets, documenting a burden of rare missense
and LoF variants in association with disease risk. In the
UKBEC, UHRF1BP1L was associated with a substantia
nigra co-expression module including both SNCA and
PINK1, reinforcing potential links with established PD
genetic mechanisms. Indeed, UHRF1BP1L knockdown
cause sharply reduced mitochondrial numbers and altered
morphology. Interestingly, UHRF1BP1L encodes a protein
bearing an amino terminal homologous to yeast VPS13
and studies in cell culture provide support for a role in
retrograde transport from the endosome to the trans-
Golgi network [60].
Notably, LoF in human VPS13C was also implicated
by our analyses of IPDGC WES data and knockdown
disrupted mitochondrial morphology. Besides the single
IPDGC case, several families with autosomal recessive
early onset Parkinsonism and dementia due to VPS13C
were recently reported [21] and this locus also harbors
common PD susceptibility variants based on GWAS [7].
Our findings of a potential mitochondrial role for
VPS13C agree with those of Lesage et al. who addition-
ally reported that VPS13C localizes to the outer mem-
brane of mitochondria and LoF was associated with
reduced mitochondrial membrane potential, fragmenta-
tion, and increased Parkin-dependent mitophagy.
Importantly, VPS35, which causes autosomal dominant,
late-onset PD, is similarly involved in endosomal traf-
ficking [61] and has also recently been implicated in
mitochondrial dynamics [62], including interactions
with Parkin [63]. Like UHRF1BP1L, VPS13C and
GPATCH2L are expressed in the brain, including within
the substantia nigra; however, additional work will be
needed to define their functions, including potential in-
teractions with other established disease genes (e.g.
VPS35, parkin) and requirements for mitochondrial
maintenance.
Based on functional screening in Drosophila, four can-
didate genes from our WES analyses were implicated as
LoF enhancers of α-synuclein neurotoxicity, which also
has a central role in PD pathogenesis. We discuss the
three genes (VPS13C, PTPRH, and ARSB) where add-
itional human genetic evidence supports replication.
Interestingly, besides its requirement for mitochondrial
maintenance, RNAi-mediated knockdown of Drosophila
Vps13 enhanced α-synuclein toxicity. In the single re-
ported VPS13C PD case with a completed autopsy,
neuropathological findings included abundant α-
synuclein aggregates in both the brainstem and cortex
[21]. Thus, VPS13C and associated endosomal sorting
pathways (including VPS35) may represent a point of con-
vergence for mitochondrial and α-synuclein-mediated PD
mechanisms. Consistent with this, evidence for the impact
of α-synuclein toxicity on mitochondria has recently
emerged [28], including from studies in mammals [64].
In the IPDGC WES cohort, a single PD case was discov-
ered with compound heterozygous LoF variants in PTPRH
(p.Q887X and p.E200X). Both variants were also observed
at low frequencies in the ExAC database (0.039% and
0.003%, respectively); however, they each met our pre-
specified threshold of < 1% based on the population
prevalence of PD. Encoding a receptor protein tyrosine
phosphatase, PTPRH (also called SAP-1) was first
discovered for its potential association with gastrointes-
tinal cancers [65, 66] and remains poorly studied in the
nervous system context. In studies of both vertebrates and
invertebrates, receptor protein tyrosine phosphatases have
been strongly implicated as key neural cell adhesion
receptors, with roles in neurodevelopment and synaptic
function, and other members of this family have been
implicated in numerous neuropsychiatric disorders [67].
In Drosophila, RNAi-mediated knockdown of the
conserved PTPRH ortholog, Ptp10D, enhanced α-
synuclein-triggered retinal degeneration, but was not
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associated with substantial neurotoxicity independent of
α-synuclein expression. Ptp10D mutant flies are also vi-
able and fertile but demonstrate long-term memory
deficits in behavioral assays [68]. More recent studies
further implicated Ptp10D in neural-glial interactions
during development of the central nervous system [69],
potentially consistent with our findings that human
PTPRH participates in a substantia nigra gene co-
expression network strongly enriched for oligodendro-
cyte markers. Besides our discovery of homozygous LoF
in PTPRH, further analyses of the IPDGC WES dataset,
and the substantially larger, independent NeuroX co-
hort, implicate a burden of rare variants at this locus in
association with PD susceptibility.
α-synuclein-induced neurodegeneration was also en-
hanced by knockdown of CG32191, a Drosophila homo-
log of ARSB. RNAi transgenic lines targeting three other
conserved fly ARSB homologs showed consistent inter-
actions with α-synuclein (Additional file 1: Table S7 and
Table S8). In the IPDGC cohort, we discovered four PD
cases homozygous for a variant predicted to disrupt spli-
cing of exons 1 and 2 in ARSB. Although the identified
variant has not previously been documented in ExAC,
we identified a single IPDGC control homozygote. Add-
itional evidence supporting association of the ARSB gene
with PD susceptibility comes from burden analysis in
the independent NeuroX cohort. The surprisingly com-
mon ARSB splicing variant (rs138279020, MAF = 0.065
in IPDGC) is a single nucleotide insertion allele within a
poly-A repeat, which we speculate might lead to ineffi-
cient capture in prior WES and possibly explain the ab-
sence of this variant from ExAC and the 1000 Genomes
project reference. All four PD cases in our data with the
homozygous ARSB splicing variant were confirmed by
Sanger sequencing. Intriguingly, mutations in ARSB,
encoding the lysosomal enzyme Arylsulfatase B, are
associated with the recessive lysosome disorder, Muco-
polysaccharidosis type VI (MPS VI, also called
Maroteaux-Lamy syndrome), in which the glycosami-
noglycan, dermatan sulfate, accumulates causing skel-
etal dysplasia and other heterogeneous manifestations
[70]. Substrate accumulation and associated cellular
stress has been reported to induce markers of im-
paired autophagy and mitochondrial dysfunction in
ARSB deficient fibroblasts from MPSVI patients, as in
other lysosomal disorders [71, 72]. Importantly,
Maroteaux-Lamy can be characterized by minimal or even
absent clinical signs, leading to incidental discovery or
diagnosis in adulthood, and such mild phenotypes have
been suggested to accompany partial LoF with preserved
low-level ARSB enzymatic activity [70, 73, 74]. Similar
genotype–phenotype relationships have been documented
for other lysosomal-storage disorders, including Gaucher’s
disease, which has established links with PD risk [75, 76].
While a full accounting is outside the scope of this study,
at least one of the three IPDGC cases for which records
were available revealed clinical features potentially over-
lapping with MPS VI.
The strengths of our study include the largest PD
WES discovery dataset assembled to date, complemen-
tary analyses in independent available cohorts to estab-
lish replication, and integration of promising human
genetic findings with multiple functional assays relevant
to PD mechanisms. Nevertheless, we also make note of
several inherent limitations. In order to prioritize candi-
date genes for initial investigation, assumptions were
made concerning the specific inheritance model (reces-
sive) and stringent criteria were employed for variant fil-
tering. In the future, it will be important to also consider
the possibility of dominantly acting alleles; however, this
substantially increases the number of variants to con-
sider and also potentially complicates functional studies
(i.e. compared with LoF screening using RNAi). Our
study design excluded consideration of many non-
synonymous variants that could potentially cause loss
(or gain) of gene function, along with certain non-
truncating, frameshifting alleles (see “Methods”). Even
with fairly stringent criteria for variant filtering and the
assumption of recessive inheritance, we found evidence
for substantial etiologic heterogeneity. Improved confi-
dence for the discovery of PD causal variants will likely
come from PD WES cohorts with significantly enhanced
sample sizes, as well as increased numbers of adult con-
trols, including those with careful neurological assess-
ments to exclude mild PD symptoms. Indeed, most of
the variants implicated by the IPDGC WES cohort were
represented at low frequencies within the largest avail-
able public database, ExAC [77, 78]; however, we have
no information about potential PD manifestations in
such individuals or even participant age.
Since no single cellular or animal experimental model
is expected to universally recapitulate all potential facets
of disease biology, we note that the employed functional
screening assays are potentially liable to false-negative or
false-positive findings. Importantly, experimental evi-
dence of a genetic interaction with either mitochondrial
dynamics or α-synuclein-mediated neuronal injury in
our screening assays cannot in isolation confirm a role
in disease causation, but rather serves to prioritize genes
for future investigation. Out of the 27 candidate genes
implicated in the IPDGC WES discovery analysis, 14
were insufficiently conserved for follow-up in α-
synuclein transgenic flies. While simple animal models,
including Drosophila or C. elegans, have made important
contributions to our understanding of PD pathogenesis,
selected mechanisms, such as the potential role of adap-
tive immunity or basal ganglia circuit dysfunction, can-
not be addressed in invertebrates [79, 80]. We were
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unable to confirm our findings from Drosophila in a
published C. elegans model of α-synuclein toxicity. In
the future, it will also be important to examine potential
genetic interactions in other PD models, including
LRRK2 transgenic flies or those containing mutations in
other PD loci, such as VPS35 or parkin. While neuro-
blastoma cells offer the convenience of robust mitochon-
drial readouts, they are limited by their undifferentiated,
transformed state distinct from that of postmitotic neu-
rons. In the future, human-induced pluripotent stem
cells, including those derived from individuals with PD,
can be differentiated into dopaminergic or other neur-
onal types and potentially deployed for functional
screening strategies. Additionally, genome-editing tech-
nologies may facilitate systematic functional evaluation
of candidate disease-associated variants of unknown
significance.
Conclusions
We have identified five excellent PD gene candidates
(GPATCH2L, UHRF1BP1L, PTPRH, ARSB, and VPS13C),
harboring homozygous or compound heterozygous LoF
variants in PD exomes, demonstrating functional interac-
tions with mitochondrial and/or α-synuclein-mediated
mechanisms, and supported by evidence of replication in
independent human datasets. The recent report [21] of
additional PD families segregating LoF mutations in
VPS13C along with other experiments supporting a role
in mitochondrial mechanisms significantly strengthens the
evidence in support of this gene in PD and validates our
overall approach. These loci are well-suited for future
efforts directed at human genetic replication and in-depth
functional dissection. We also make available results, in-
cluding findings from human genetic analyses and func-
tional studies in most cases, on 22 other promising loci.
These data will serve as a valuable reference for ongoing
and future PD genetic studies. More broadly, our ap-
proach of integrating high-throughput sequencing in PD
case/control cohorts with parallel systematic screening in
cells and model organisms for functional prioritization ex-
emplifies a powerful experimental strategy with great
promise for future genomic studies of PD and other hu-
man disorders.
Methods
Genetic analyses
Whole-exome sequencing
WES was performed on 1148 PD cases and 503 neuro-
logically healthy controls of European descent. All par-
ticipants provided written informed consent. Relevant
local ethical committees for medical research approved
participation in genetic studies. If PD patients were
prescreened for known pathogenic mutations, they were
excluded for exome sequencing when having such a
variant. The cases were diagnosed with PD at a relatively
young average age of 40.6 years (range, 6–56 years), of
which approximately 37% reported a positive family his-
tory. The neurologically healthy controls are on average
48.2 years of age (range, 10–97 years). A more extensive
overview of demographic information is reported in
Additional file 2: Figure S8.
Due to improvements of the exome sequencing proto-
col over time, the exome sample libraries were prepared
with different capture kits. For this study, three different
capture kits were used: Illumina TruSeq (San Diego, CA,
USA) (62 Mb target); Roche (Basel, Switzerland) Nim-
blegen SeqCap (44.1 Mb target); and Agilent (Santa
Clara, CA, USA) SureSelect (37.6 Mb target), which cap-
tured 96%, 81%, and 71% of the targeted exome at least
ten times, respectively (Additional file 1: Table S12).
Exome libraries were sequenced on a HiSeq 2000 (Illu-
mina, San Diego, CA, USA). The Burrows Wheeler
Aligner MEM v0.7.9.a [81] was used to align the 100-bp
paired-end reads to the human reference genome build
hg19. We called the single nucleotide variants (SNVs)
and insertions/deletions (indels) for all samples simul-
taneously using Genome Analysis Toolkit (GATK) 3.x
[82], followed by the exclusion of low-quality variant
calls not passing the default GATK filters. Individual
genotypes were removed with genotype quality Phred-
scores below 40. ANNOVAR [83] was applied to anno-
tate the variants with information concerning variant
type (valid annotations when Refseq in concordance
with UCSC), MAF in the general population, and predic-
tions of the variant’s effect on gene function, implement-
ing CADD [84].
Variant identification in IPDGC WES dataset
Considering the worldwide prevalence of 0.041% for PD
in the age range of 40–49 years [20], we selected rare
variants with a MAF < 1% (corresponding to a homozy-
gous frequency of 0.01%) in the European population.
Because the specified 0.041% of the population with
young-onset Parkinson’s disease (YOPD) is not caused
by one shared genetic factor, we expect a homozygous
frequency of 0.01% to be an adequate cutoff, which
would be able to determine variants present in approxi-
mately 25% of the YOPD population. As a comparison
to the most common genetic cause of YOPD, parkin
[85], the most frequent mutation is an exon 3 deletion,
which has been identified in 16.4% of YOPD patients
[86]. Using ANNOVAR [83], all variants were annotated
with MAF information of ESP6500si (European Ameri-
can population) [87], 1000 Genomes Project (European
population of April 2012 version) [88], and the ExAC
browser (non-Finish European population) [77, 78].
When no public allele frequency was available for homo-
zygous variants, the in-house control dataset of 503
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individuals was used as a reference for the general popu-
lation. Homozygous variants were excluded when being
common (>1%) in controls or having a relative higher
frequency in controls than in cases. KGGseq [89] was
used to count the number of homozygous variants for
the cases versus controls.
In addition to the population allele frequency filters,
we only selected SNVs and indels affecting the position
of the stop codon or located at a splice site (within 2 bp
of splicing junction), which are variants expected to re-
sult in a loss of gene function. As the aim of this study
was to validate our approach to identify high promising
PD candidate genes, rather than discovering all putative
PD genes present within our WES dataset, we set a con-
servative selection criteria by only including frameshifts
that caused an immediate stopcodon at the position of
the indel. Splice-site variants were only considered when
being adjacently located to an exon that is coding for
amino acids. As a final filter for the homozygous vari-
ants, we manually excluded variants that failed
GATKVQSR and hard filtering. Quality predictions
based on the ExAC database are more adequate, as it
includes ~37× more samples than our dataset.
For the putative compound heterozygous mutations,
both variants should be located within the same tran-
script and at least one allele should contain a LoF vari-
ant. The second variant could be: (1) a LoF variant; or
(2) a missense variant that is absent in dbSNP137 [90]
database and with a CADD score > 20 (predicted to be-
long to the 1% most deleterious variants of the total gen-
ome), indicating a pathogenic effect. The latter two filter
criteria should decrease the chance of including benign
missense variants. The putative compound heterozygous
variants were identified by scoring the number of vari-
ants per sample per gene with PSEQ (https://atgu.mgh.-
harvard.edu/plinkseq/pseq.shtml). The reads of variants
located within approximately 200 base pairs were visual-
ized in IGV [91] to judge the authenticity of the com-
pound heterozygous variant. When the different variants
are located on distinct alleles, the combination of vari-
ants was considered a true compound heterozygous
mutation.
All recessive variants that remained after the filtering
procedures were Sanger sequenced to confirm the vari-
ant calls generated by the exome pipeline.
Variant aggregation analyses in the IPDGC WES dataset
SKAT-c [92] was used to analyze the burden of coding
variants for each identified gene. Both rare variants only
and the joint effect of common and rare variants were
tested. Because variant aggregation tests are prone to
coverage differences, capture usage and population
stratification, we performed a more stringent individual
and variant QC, resulting in a reduced dataset of 1540
samples (1062 cases and 478 controls) covering 268,038
variants. Individuals were excluded when failing gender
test, showing evidence of relatedness, having dubious
heterozygosity/genotype calls, or being a population out-
lier. Variants were removed when having a genotype
missingness > 5%, a Hardy–Weinberg equilibrium p
value < 1e−6 or a p value for non-random missingness by
phenotype < 1e−5. Variants were only considered for as-
sociation analyses if located in a region targeted by all
different capture kits.
Benign variants have the potential to dilute a true as-
sociation signal of the combined effect of functional var-
iants in a gene. We therefore annotated variants with
ANNOVAR [83] to group variants according to their
type or predicted pathogenicity. Two subsets of variants
were examined: (1) predicted pathogenic variants, in-
cluding LoF variants and missense mutations that are
predicted to be pathogenic by the CADD framework;
and (2) missense variants, including amino-acid chan-
ging and LoF variants.
As suggested by SKAT, we selected a MAF cutoff of
0.018, which is based on the total sample size and sepa-
rates rare and common variants. Common variants
(MAF > 0.018) were pruned using PLINK [93] (indep
settings 50 5 1.5). Due to confounding factors (usage dif-
ferent capture kits and multiple CEU populations), 20
principle components, 10× coverage, and gender were
taken into account as covariates. Both a traditional
one-sided burden (assuming all variants to have a
harmful effect) and a two-sided SKAT test (allowing
variants to be either damaging or protective) were per-
formed. Empirical p values were calculated by compari-
son of the nominal p value to 10,000 permutations of
affection status. Genes with an empirical p value < 0.05
were considered to be significantly associated to PD.
Genetic replication 1: variant identification in
PPMI WES dataset
We obtained permission to access WES data generated
by the PPMI [51]. After standard variant and individual
QC, the dataset includes 477,512 variants for 462 PD
cases and 183 neurologically healthy controls. A similar
search for homozygous and putative compound hetero-
zygous LoF variants, as described for the original IPDGC
WES dataset, was applied for this second independent
PPMI WES dataset by using ANNOVAR [83] and
KGGSeq [89].
Genetic replication 2: GRIP genetic isolate
The southwest of the Netherlands contains a recently
isolated population which is part of the GRIP program
[52]. A total of 39 PD index cases and 19 controls of this
isolate were subjected to whole-genome sequencing to
explore the genetic factors underlying PD within this
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geographic region. Missense and LoF variants which
were present in at least two index cases and a MAF <
0.1% in public databases (ExAC, 1000G dbSNP138, and
ESP6500) were considered as potential PD variants.
Genes harboring such variants were surveyed for overlap
with our list of candidate genes.
Genetic replication 3: variant aggregation analyses
in NeuroX
We investigated the genetic burden of common and rare
variants in these genes by using the independent Neu-
roX dataset, which is generated by a custom-made geno-
type array [53] using a backbone of ~240,000 standard
Illumina Exome content as a basis with an additional
~24,000 variants that are suggested to be involved
neurological diseases. The same procedures as described
for the burden test in the IPDGC WES dataset were ap-
plied. After QC, a total of 6801 PD cases and 5970
neurologically healthy controls remained with high-
quality genotype data for 178,779 variants. Based on the
sample size, the MAF cutoff was 0.0063.
Genetic replication 4: overlap PD risk loci
Approximately 70% of the participants included in this
study have also been included in previous published
GWAS [7, 94, 95]. To explore the possibility that our
candidate genes might also contain common risk vari-
ants increasing the risk to develop PD, next to the iden-
tified LoF variants with assumed high penetrance, we
searched for GWAS loci within 1 Mb upstream and
downstream of the gene of interest using the recent PD
meta-analysis through pdgene.org [7]. Significant associ-
ations and suggestive p values < 1e-4 were considered.
To understand the underlying linkage disequilibrium
structure, LocusZoom [96] was applied to visualize the
European 1000G recombination events for the candidate
genes that were closely located to a GWAS locus.
Gene co-expression analyses
We constructed gene co-expression networks (GCN)
from two different substantia nigra datasets using the R
software package, WGCNA (weighted gene co-
expression network analysis) [97]. This was followed by
the same post-processing of WGCNA gene modules
based on k-means: a heuristic to rearrange misplaced
genes between modules using the number of modules
detected by the standard WGCNA as k and the eigen-
genes as centroids. The first GCN is based on 19,152
genes from 65 substantia nigra control brains from the
UKBEC consortium. The gene expression profiles are
based on Affymetrix Exon 1.0 ST Arrays [98]. The sec-
ond GCN is based on 63 samples from the same tissue,
GTEx [56] V6 gene RPKM values. Genes were filtered
with a RPKM based cutoff of 0.2 and missingness < 30%
resulting in the analysis of 18,363 Ensembl genes. We
corrected this gene expression dataset for the principal
components significantly correlated with GTEx samples
covariates using the Swamp R package. WGCNA gene
modules were functionally annotated with gProfileR
[99] R software package using GO database, accounting
for multiple testing with gSCS’s gProfiler test. Back-
ground genes used were all genes in the substantia nigra
GCN. Cell type enrichment analysis was performed with
the userListEnrichment function with brain specific en-
richment, implemented in the WGCNA R package. Pres-
ervation analysis of UKBEC GCN in GTEx’s substantia
nigra profiles was performed with WGCNA’s preservation
analysis. Results are reported with the Z.summary statistic
[100]. Graphical representation of the GCN subnetworks
were constructed by using the 27 candidate genes and
known PD genes (ATP13A2, FBXO7, LRRK2, PARK2,
PARK7, PINK1, RAB39B, SNCA, and VPS35) as seed
genes. For each of these genes sequentially, in a round
robin fashion, we added the gene with highest adjacency,
based on TOM values, and the links this gene has with all
the seed genes. We used Cytoscape 3.3 for display with a
Kamada-kawai layout algorithm [101].
Human cellular screen
shRNA virus production
Bacterial glycerol stocks containing the shRNA vectors
(Sigma, St. Louis, MO, USA; TRC1 and 1.5) were grown
overnight in Luria-Bertani media containing 100 μg/mL
of ampicillin (Sigma-Aldrich, St. Louis, MO, USA). We
selected at least five shRNA clones per gene. Endotoxin-
free shRNA plasmids were extracted according to the
manufacturer’s protocol (Zymo, Irvine, CA, USA; ZR
Plasmid Miniprep Classic kit). Lentivirus was produced
as follows: HEK293T packaging cells were seeded at a
density of 4 × 10Δ5/mL (100 μL per well) in cell culture
media, Optimem (Invitrogen, Carlsbad, CA, USA) con-
taining 10% fetal bovine serum (FBS) in 96-well tissue
culture plates. Cells were incubated for 24 h (37 °C, 5%
CO2). Each well was subsequently transfected with
100 ng of shRNA plasmid, 90 ng of packaging plasmid
(pCMV-dr8.74psPAX2), and 10 ng of envelope plasmid
(VSV-G/pMD2.G) combined with 0.6 μL of FugeneHD
(Promega, Madison, WI, USA) in a total volume of
10 μL. Transfection efficiency was monitored using the
pKLO.1 GFP plasmid (Sigma, St. Louis, MO, USA) and
had to be greater than 90%. Sixteen hours after transfec-
tion, media was refreshed and supernatant harvested
after a further 24 h. Virus was stored at −80 °C.
To ensure successful lentivirus production, HEK293T
cells were plated out at a density of 2 × 10Δ5/mL (100 μL
per well) in Optimem containing 10% FBS and 15 μg/
mL of protamine sulfate (Sigma, St. Louis, MO, USA).
Cells were infected with 10 μL, 25 μL, and 50 μL of
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lentivirus. The following day, media was refreshed with
media containing 2.5 μg/mL of puromycin. After a fur-
ther three days, plates were manually inspected to deter-
mine cell viability of each well. If more than 10% of the
wells contained dead cells, lentiviral production for that
plate was repeated.
Neuroblastoma cell culture
BE(2)-M17 (ATCC® CRL-2267™) and HEK 293 T
(ATCC® CRL-3216™) cell lines were obtained from the
American Type Culture Collection (Manassas, VA,
USA). BE(2)-M17 cell lines were cultured in Dulbecco’s
Modified Eagle/Nutrient Mixture F-12 Medium
(DMEM/F-12) with GlutaMAX (Invitrogen, Carlsbad,
CA, USA) supplemented with 10% FBS, 1× non-essential
amino acids (NEAA), and 1% Penicillin/Streptomycin.
HEK 293 T cells were cultured in Opti-MEM (Invitro-
gen, Carlsbad, CA, USA) containing 10% FBS and 1×
NEAA. All cell lines were routinely tested for myco-
plasma contamination. For lentivirus infection, 25 μL of
the lentivirus was added to each well of a 96-well plates
and protamine sulfate was added at a final concentration
of 1 μg/mL in each well of the 96-well plate. Specific
wells on each lentiviral plate contained GFP expressing
virus to ensure efficient transduction.
Cell-based screening assays
Four phenotypes were studied in two different assays:
Mitochondrial morphology [33] was examined in a
single assay with BE(2)-M17 cells, which were expanded
and plated at a density of 5 × 10Δ4/mL (100 μL per well)
in 96-well black CellCarrier plates (PerkinElmer,
Waltham, MA, USA) pre-pipetted with 25 μL of the
lentivirus. On day 2, media was refreshed with DMEM/
F12 (with 10% FBS) supplemented with 2 μg/mL puro-
mycin. On day 4, the cells were incubated with 100 nM
MitoTracker Red CMXros, 100 nM MitoTracker
DeepRed (Molecular Probes), and 1 μg/mL Hoechst for
20 min at room temperature. Media was refreshed and
the cells were incubated for a further 2 h before fixation
with 4% paraformaldehyde (pH 7.3).We examined three
parameters commonly used for quantification of mito-
chondrial morphology: mitochondrial number, axial
length ratio, and roundness.
For the Parkin translocation assay BE(2)-M17 cells
were also utilized. The PLVX inducible vector (Clontech,
Mountain View, CA, USA) overexpressing C-terminally
tagged Parkin-GFP was used to make polyclonal stable
BE(2)-M17 cells. Stable cell lines were cultured in
DMEM/F12 supplemented with 10% FBS, 1% NEAA, 1%
P/S, 250 ng/mL Puromycin, 200 μg/mL G418, and 1 μg/
mL of doxycycline. BE(2)-M17 cells were expanded and
plated at a density of 7.5 × 10^4/mL (100 μL per well) in
96-well black CellCarrier plates (PerkinElmer, Waltham,
MA, USA) pre-pipetted with 25 μL of the lentivirus. The
following day, media was exchanged with media without
doxycycline to induce the expression of Parkin-GFP. On
day 5, the cells were incubated with 100 nM Mito-
Tracker DeepRed (Molecular Probes, Eugene, OR, USA)
and 1 μg/mL Hoechst. After 20 min, media was
refreshed with media containing 15 μM Carbonyl cyan-
ide m-chlorophenyl hydrazone (CCCP). Cells were incu-
bated for 2 h before fixation in 4% paraformaldehyde
(pH 7.3).
Image acquisition and analysis
Image acquisition was carried out using the automated
confocal imaging system, Cell Voyager CV7000 (Yoko-
gawa, Tokyo, Japan). The mitochondrial morphology
assay involved a total of 60 fields per well using a 60×
water immersion objective lens for improved reso-
lution. Nuclei were imaged utilizing the 405 nm laser,
Mitotracker CMXros utilizing the 561 nm laser, and
mitotracker DeepRed utilizing the 640nM laser. For the
translocation assay, a total of 60 fields per well were
taken using a 20× objective lens. Nuclei were imaged
utilizing the 405 nm laser, Parkin-GFP utilizing the
488 nm laser, and mitotracker DeepRed utilizing the
640 nm laser.
Images were stored and analyzed by the Columbus
Image Data storage (PerkinElmer, Waltham, MA, USA).
Image quality control: only well-segmented interphase
cells were included. Mitotic, apoptotic badly segmented,
and out-of-focus cells were excluded. Cells touching the
border of the image were removed to avoid analysis of
artificially cropped cells. All wells where the perturb-
ation strongly decreased cell number were disregarded.
Morphological characteristics and signal intensities were
quantified and results exported to R package CellHTS2.
To quantify mitochondrial morphology, the median
mitochondrial number per object, roundness, axial
length ratio, and intensity of mitorackerCMXros (mito-
chondrial potential) were calculated.
To differentiate between CCCP-treated Parkin stable
cell lines and untreated cells, the number of spots
formed on mitochondria was calculated. Cells containing
more than two spots were considered positive for Parkin
translocation. The ratio of cells positive for translocation
versus the number of cells negative for translocation was
calculated per well to give a cell number independent
measure of Parkin translocation. CCCP-treated cells
transduced with a scrambled shRNA and CCCP-treated
cells transduced with shRNA targeting PINK1 were in-
cluded on each plate. An average Z’ of 0.61 was calcu-
lated for the entire screen, with a minimum Spearman’s
Rank correlation between replicates of 0.8.
Data from high content imaging assays were analyzed
using the BioConductor CellHTS2 package for the R
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software environment (R version 2.11.1, BioConductor
version 2.6). Data were normalized to negative controls
on a per-plate basis to minimize plate-to-plate vari-
ation. For the Parkin-translocation screen, negative
controls were considered as wells which had been
transduced with lentivirus encoding a scrambled se-
quence and had been treated with CCCP. For the
remaining screens, negative controls were considered
as wells that had been transduced with lentivirus en-
coding a scrambled sequence.
Statistical analysis
For each of the shRNA screens, each assay plate was
completed with six replicates to enable the detection of
subtle effects and minimize false negatives. For each
shRNA, Mann–Whitney U tests with false discovery rate
(FDR) correction were performed and the robust strictly
standardized median difference (SSMD*) was calculated
[102]. Effects were considered significant when the
SSMD* normalized effect of shRNA treatment was
greater than or less than 4 or −4 and at least two inde-
pendent clones per gene showed a significant effect.
Seed sequences were manually inspected to ensure no
common sequence.
For each assay, a positive control plate containing
known modifiers of the phenotype in question was run
in parallel to ensure the assay worked optimally. The ro-
bust Z-factor was calculated as previously described
[103], using the normalized values for the controls from
all plates. For the mitochondrial assay, known regulators
of mitochondrial fission or fusion were included. For the
Parkin translocation assay, TOMM7 and PINK1 were
used as positive controls.
shRNA knockdown validation
Cell culture and shRNA mediated knockdown were
performed as described above. Cells were harvested for
RNA isolation using the SV 96 Total RNA Isolation
System (Promega, Madison, WI, USA) according to the
manufacturer’s protocol. Total RNA primed with oligo
dT (Qiagen, Hilden, Germany) was used for cDNA syn-
thesis with Superscript III RT (Life Technologies,
Carlsbad, CA, USA) according to the manufacturer’s
specifications. Quantitative polymerase chain reaction
(PCR) was carried out in triplicates on a ViiA7 real-
time PCR system using SYBR Green PCR master mix
(Life Technologies, Carlsbad, CA, USA) and 0.04 μM
specific primer pairs for all targets. For multiple exons,
gene primers were designed to span exon-exon junc-
tions or to be separated by one intron on the corre-
sponding genomic DNA. Normalized relative quantities
were calculated with HMBS as housekeeping gene by
using the qbasePLUS software (Biogazelle, Gent,
Belgium) and knockdown efficiencies per clone were
calculated using scrambled control wells (n = 3) as a
reference.
Animal models
Orthologue selection
The function of the candidate genes and their involve-
ment in neurodegeneration was tested in two animal
models; C. elegans and Drosophila. The DRSC Integrated
Ortholog Prediction Tool (DIOPT) [104] was used to
identify the conserved homologs of human genes in the
nematode or fly genomes. Orthologues were defined
based on a minimum unweighted DIOPT score of 2,
such that two independent bioinformatics algorithms
were in agreement concerning the orthologue pairing. In
cases where multiple genes were identified as potential
orthologues for a given human gene, we carried forward
all candidates with DIOPT scores greater than 3.
Fly stocks and husbandry
The human α-synuclein transgenic flies with codon-
optimization for Drosophila (UAS-α-synuclein line #7),
were recently described [48] and are available from the
Bloomington Stock Center (Bloomington, IN, USA).
RNAi transgenic lines were obtained from the Vienna
Drosophila RNAi Centre (Vienna, Austria) or from
Bloomington for the Harvard Transgenic RNAi Project.
All RNAi lines used for this study are detailed in Add-
itional file 1: Table S8. The GAL4-UAS system [105] was
used for ectopic co-expression of both the α-synuclein
and RNAi transgene. The Rh1-Gal4 driver line (second-
chromosome insertion) has been previously described
[48, 106]. For screening, individual RNAi (IR) lines or
Canton S (as a control) were crossed to animals of the
genotype: Rh1-Gal4/CyO; UAS-Syn/TM6B. All crosses
were established at 18 °C and F1 experimental animals
(Rh1-Gal4 / UAS-IR; UAS-Syn / + or Rh1-Gal4 / +;
UAS-Syn / UAS-IR) were shifted to 25 °C within 24 h of
eclosion and aged 15 days. To examine for potential α-
synuclein independent retinal degeneration, each UAS-
IR transgenic line was separately crossed to Rh1-Gal4,
using identical conditions. Based on the results of
the primary RNAi screen, we also obtained from
Bloomington available mutant alleles for the fly
orthologues of PTPRH: Ptp10D and Ptp4E. The fol-
lowing additional stocks were used: (1) w, Ptp4E1;
(2) w, Ptp10D1; (3) yw, Ptp4E1, Ptp10D1 / FM7C. All
experimental results were quantified and photo-
graphed in female animals.
Characterization of retinal degeneration in Drosophila
For optical neutralization (also known as the pseudopu-
pil preparation), fly heads of 15-day-old animals were
immersed in mineral oil and transilluminated using a
40× objective on a Leica (Wetzlar, Germany) DM6000B
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light microscope. Eyes from at least four animals were
examined per genotype (at least eight retinae). All candi-
date modifier lines and controls were scored blinded by
three independent examiners. The penetrance of
degeneration caused by each RNAi line was calculated
by dividing the number of abnormal retinae, showing
evidence of either reduced rhabodomere numbers or
altered refraction of light indicative of vacuolar
changes, by the total number of retinae examined. For
identification of genetic enhancers, we required two
independent RNAi lines targeting non-overlapping se-
quences with 50% or greater degenerate retinaes ob-
served using the pseudopupil assay. Following our
initial screen of two RNAi lines targeting each of 18 fly
gene homologs, additional RNAi lines and mutant
strains were evaluated, where possible, for the most
promising candidates. For each enhancer gene, the
strongest RNAi line was independently re-tested for
consistency using the pseudopupil assay and retinal
histologic sections were also performed for further
confirmation. To examine for potential α-synuclein-
independent retinal degeneration, the strongest RNAi
modifier for each gene was separately crossed to Rh1-Gal4
and histologic sections were examined for 15-day-old ani-
mals. For histology, fly heads from 15-day-old animals
were fixed in 8% glutaraldehyde and embedded in paraffin.
Tangential (3 μm) retinal sections were cut using a Leica
Microtome (RM2245) and stained with hematoxylin and
eosin. Retinae from at least three animals were examined
and quantified per genotype. Enhancement of α-synuclein-
induced retinal degeneration was quantified based on the
severity of retinal vacuolar changes seen in stained histo-
logic sections. We examined representative photographs
taken with a 40× objective from well-oriented, intact tan-
gential sections at a depth in which the retina achieves
maximal diameter. Using ImageJ software [107], we re-
corded the area occupied by all vacuoles with a diam-
eter greater than 4 μm and divided by the total retinal
area to compute a percentage. Statistical comparisons
were implemented using a two-tailed student’s t-test.
α-synuclein expression levels were determined by im-
munoblot (clone 42, 1:1000, BD Transduction Labora-
tories, San Diego, CA, USA).
C. elegans media and strains
All strains were maintained as described previously
[108]. For this study, the worm strains N2 (wild-
type), CF512 (fer-15(b26)II; fem-1(hc17)III), and
OW40 (zgIs15[P(unc-54)::α-synuclein::YFP]IV) were
used. Strains were grown at 20 °C on Nematode
Growth medium (NGM) seeded with Escherichia coli
stain OP50. For each orthologue, one RNAi clone
was selected to target the corresponding gene.
Phenotype assays for basal phenotypes in C. elegans
The systematic RNAi screen was carried out as de-
scribed [109]. RNAi clones targeting the genes of inter-
est (9/27; Additional file 1: Table S3) were obtained from
the Vidal cDNA RNAi library or the Ahringer RNAi li-
brary. Bacteria expressing the empty vector L4440 were
used as negative control. For the survival assay, we
employed a sterile strain, CF512 (fer-15(b26); fem-
1(hc17)) [110]. To induce sterility, eggs were collected
and kept in M9 medium at 25 °C overnight until they
reached L1 arrest. Approximately 25 L1 worms were
added to plates seeded with RNAi clones of interest and
empty vector control and allowed to develop to adults at
25 °C. At day 9 of adulthood at 25 °C, when approxi-
mately half of the worms grown on control plates were
dead, the survival of worms on RNAi plates was
determined.
The offspring and developmental phenotypes were
tested in a single assay. N2 worms were grown at 20 °C
until L4 stage on OP50 bacteria and then transferred to
plates seeded with RNAi clones of interest and empty
vector control. At day 2 of adulthood, ten worms were
put onto a new plate seeded with the same RNAi clone
for 1 h to produce progeny. The plates containing the
progeny were kept at 20 °C until the F1 generation of
the control worms reached L4 stage. The number and
developmental phenotypes of the offspring were scored
at the last time point using a dissecting microscope. A
one-sided student’s t-test was used to determine the sig-
nificant changes compared to controls. All counting was
done in a blind fashion in which the identity of the sam-
ples was concealed and each experiment was performed
in three biological replicates.
Motility assay for α-synuclein toxicity model in C. elegans
Animals were age-synchronized by hypochlorite treat-
ment, hatched overnight in M9 buffer, and subsequently
cultured on NGM containing isopropylthio-β-D-galacto-
side (IPTG, 15 mg/L) and 50 μg/mL ampicillin (plates
for RNAi treatment). Plates were seeded with RNAi bac-
teria. Prior to the experiment, the plates were kept at
room temperature for two days to allow the production
of dsRNA by the bacteria. On day 1 of adulthood (one
day after larval stage L4), animals were transferred to
RNAi plates containing 5-fluoro-2’deoxy-uridine (FUDR)
to prevent the offspring from growing. RNAi clones
targeting C54D2.4 (ARSB), T08G11.1 (VPS13C), and
F44G4.8 (PTPRH) were used from the Ahringer C. ele-
gans RNAi library. All clones were verified by sequen-
cing. RNAi clones for the C. elegans orthologue F21F3.7
(TMEM134) was not available.
Animals were scored at day 4 and day 8 of adulthood.
Animals were placed in a drop of M9 and allowed to ad-
just for 30 s, after which the number of body bends was
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counted for another 30 s. Fifteen animals were scored
per condition. Relative body bends were calculated by
normalizing to control values. Error bars are showing
the standard error of mean. Assays were repeated in
three independent experiments and the relative body
bends of one representative experiment is shown.
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